Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells 3,635 Shares of Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insider Dallan Murray sold 3,635 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the transaction, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sarepta Therapeutics Price Performance

SRPT traded up $1.38 during trading on Monday, hitting $135.04. The company’s stock had a trading volume of 823,407 shares, compared to its average volume of 1,015,505. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $12.76 billion, a price-to-earnings ratio of 1,227.64 and a beta of 0.95. The business’s fifty day simple moving average is $125.63 and its 200 day simple moving average is $110.74. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm’s revenue was up 63.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.44) EPS. On average, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. GAMMA Investing LLC grew its stake in Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 87 shares in the last quarter. Vanguard Capital Wealth Advisors increased its holdings in shares of Sarepta Therapeutics by 3.8% in the fourth quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 90 shares during the last quarter. DMC Group LLC lifted its position in Sarepta Therapeutics by 2.9% during the third quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock worth $400,000 after buying an additional 93 shares in the last quarter. Riggs Asset Managment Co. Inc. boosted its stake in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares during the last quarter. Finally, WCM Investment Management LLC grew its holdings in Sarepta Therapeutics by 2.3% in the 1st quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after buying an additional 142 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. BMO Capital Markets initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 31st. They set an “outperform” rating and a $170.00 price target on the stock. Royal Bank of Canada upped their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. Mizuho boosted their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. JPMorgan Chase & Co. reduced their target price on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday. Finally, TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $160.60.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.